ACT017
ACT017 is a Fab fragment of humanized anti-GPVI monoclonal antibody. ACT017 inhibits collagen-induced platelet aggregation. ACT017 has the potential for the research of acute ischemic stroke[1][2].
Product Specifications
CAS Number
[2101829-58-5]
UNSPSC
12352203
Target
Glycoprotein VI
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/glenzocimab.html
Purity
99.00
Solubility
10 mM in DMSO
Smiles
[ACT017]
Molecular Weight
(48.29 kDa)
References & Citations
[1]Wichaiyo S, et al. Glenzocimab: A GPVI (Glycoprotein VI) -Targeted Potential Antiplatelet Agent for the Treatment of Acute Ischemic Stroke. Stroke. 2022 Nov;53 (11) :3506-3513. |[2]Lebozec K, et al. Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks. MAbs. 2017 Aug/Sep;9 (6) :945-958.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
334768 100 µL
SMAD9 (SMAD Family Member 9, PPH2, Mothers Against Decapentaplegic Homolog 9, MADH6, MADH9, SMAD8, SMAD8A, SMAD8B)
Ask
View Details 
MBS6363836-01 0.1 mL
WWC1, NT (WWC1, KIAA0869, Protein KIBRA, HBeAg-binding protein 3, Kidney and brain protein, WW domain-containing protein 1) (MaxLight 490)
Ask
View Details 
MBS6363836-02 5x 0.1 mL
WWC1, NT (WWC1, KIAA0869, Protein KIBRA, HBeAg-binding protein 3, Kidney and brain protein, WW domain-containing protein 1) (MaxLight 490)
Ask
View Details 